C4 Therapeutics Inc(CCCC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 5:10 PM ET (Korea 10/29 06:10)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1 | Insider Own | 8.05% | Shs Outstand | 122.9M | Perf Week | 7.1% |
| Market Cap | 0.42B | Forward P/E | - | EPS next Y | -9.35% | Insider Trans | - | Shs Float | 113.1M | Perf Month | 8.47% |
| Enterprise Value | 0.22B | PEG | - | EPS next Q | -0.19 | Inst Own | 97.06% | Short Float | 37.77% | Perf Quarter | -7.24% |
| Income | -0.10B | P/S | 11.92 | EPS this Y | 33.97% | Inst Trans | 30.36% | Short Ratio | 17.81 | Perf Half Y | 32.62% |
| Sales | 0.04B | P/B | 1.69 | EPS next 5Y | 4.97% | ROA | -30.92% | Short Interest | 42.72M | Perf YTD | 77.75% |
| Book/sh | 2.01 | P/C | 1.65 | EPS past 3/5Y | 21.55% 3.84% | ROE | -48.14% | 52W High | -34.33% ($5.17) | Perf Year | 31.59% |
| Cash/sh | 2.06 | P/FCF | - | Sales past 3/5Y | 4.95% 1.61% | ROIC | -34.1% | 52W Low | 100.88% ($1.69) | Perf 3Y | 144.24% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 36.86% | Gross Margin | 78.68% | Volatility(W/M) | 5.45% 7.32% | Perf 5Y | -92.61% |
| Dividend TTM | - | EV/Sales | 6.3 | Sales Y/Y TTM | 2.33% | Oper. Margin | -288.34% | ATR (14) | 0.22 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.45 | EPS Q/Q | 50.66% | Profit Margin | -289.44% | RSI (14) | 58.32 | Recom | 1.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.45 | Sales Q/Q | 2.75% | SMA20 | 13.49% ($2.99) | Beta | 3.19 | Target Price | $12.62 |
| Payout | - | Debt/Eq | 0.23 | Earnings | 2026/8/11 | SMA50 | 1.21% ($3.35) | Rel Volume | 1.71 | Prev Close | $3.21 |
| Employees | 104 | LT Debt/Eq | 0.2 | EPS/Sales Surpr. | 20.49% 66.03% | SMA200 | 6.18% ($3.19) | Avg Volume(3M) | 2.40M | Price | $3.39 |
| IPO | 2020/10/2 | Option/Short | Yes/Yes | Trades | 8982 | Volume | 4,105,524 | Change | 5.76% |
🧬 A US clinical-stage biotech company developing oral degrader-based new drugs based on targeted protein degradation technology. It possesses a degrader platform that directly eliminates disease-causing proteins and is expanding its pipeline with a focus on hematologic cancers and solid tumors.
Over the past 1 year, roughly in the middle
34% below its 1-year high.
Traded more than usual. That is 171% of its average volume.
CCCC has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +34.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,192. Peers typically go for $1,237.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -92.6%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
37.8% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #236 of 594 in the industry
Based on market cap of $418M.
ASMB#235 Assembly Biosciences Inc $418M PER - CCCC#236 C4 Therapeutics Inc $418M PER - 
ZURA#237 Zura Bio Ltd $417M PER - 
RZLT#238 Rezolute Inc $409M PER - 
ALT#239 Altimmune Inc $408M PER - 
FAQ
What kind of company is CCCC?
CCCC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CCCC?
The market cap of CCCC is approximately $418M, ranking 3,310 within its sector.
What is the 52-week high and low for CCCC?
CCCC has recorded a 52-week high of $5.17 and a low of $1.69.
